Too many vessels? Not enough? The wrong kind? The VEGF debate continues.
J. Anthony Ware
Departments of Molecular Pharmacology and Cardiology Albert Einstein College of Medicine Montefiore Medical Center Bronx, New York, USA
jaware@aecom.yu.edu
Although angiogenic factors provide hope for patients with ischemic diseases, a whirlwind of controversy surrounds their purported involvement in development of atherosclerosis (pages 425−429).
